Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17049237 | USE OF A HYALURONIC ACID-BASED HYDROGEL FOR TREATMENT OF VOLUMETRIC MUSCLE LOSS INJURY | Non-Final OA | The Regents of The University of California |
| 19358715 | GLP-1R ANTAGONISM TO IMPROVE NUTRITION FOLLOWING GASTROINTESTINAL SURGERY | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17430664 | CO-FORMULATIONS OF AMYLIN ANALOGUES WITH INSULIN ANALOGUES FOR TREATMENT OF DIABETES | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17416584 | NUTRITIONAL COMPOSITION FOR INDUCING A FEELING OF SATIETY, A BETTER SLEEP AND/OR LIMITING NOCTURNAL AWAKING IN INFANTS OR YOUNG CHILDREN | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 18019847 | CHEMICAL SYNTHESIS OF LARGE AND MIRROR-IMAGE PROTEINS AND USES THEREOF | Non-Final OA | Tsinghua University |
| 17348694 | DIMERIC COLLAGEN HYBRIDIZING PEPTIDES AND METHODS OF USE THEREOF | Non-Final OA | University of Utah Research Foundation |
| 17630628 | ALGINATE-BASED MICROCAPSULATION FOR THE DELIVERY OF ALPHA-CGRP IN CARDIOVASCULAR DISEASES | Non-Final OA | University of South Carolina |
| 17762191 | INTEGRIN RECEPTOR ALPHA V BETA 3 AND ITS LIGAND INVOLVED IN CHRONIC ITCH | Final Rejection | North Carolina State University |
| 17788488 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC BONE DISEASES, COMPRISING GLP-2 OR CONJUGATE THEREOF | Non-Final OA | HANMI PHARM. CO., LTD. |
| 16762058 | Silk Alcohol Formulations | Non-Final OA | GIVAUDAN SA |
| 18027331 | METHODS OF TREATING EYE DISORDERS | Non-Final OA | Apellis Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy